June 2015 June 2015
New Product - Simbrinza eye drops
Simbrinza eye drops (brinzolamide, brimonidine tartrate) contains a carbonic anhydrase inhibitor and an alpha‑2 adrenergic agonist respectively that lower the intraocular pressure (IOP) by suppressing the formation of aqueous humour from the ciliary process in the eye. Brinzolamide acts by inhibiting the enzyme carbonic anhydrase in the ciliary epithelium and brimonidine inhibits the enzyme adenylate cyclase and suppresses the cAMP‑dependent formation of aqueous humour. Additionally, brimonidine causes an increase in uveoscleral outflow. Simbrinza is indicated in the reduction of elevated intraocular pressure (IOP) in adult patients with open‑angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. It is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy; patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin); severe renal impairment and hyperchloraemic acidosis. Simbrinza is also contraindicated in children under the age of 2 years. Simbrinza is available as a 5 ml Drop‑Tainer containing 10 mg/ml of brinzolamide and 2 mg/ml of brimonidine tartrate.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au